Table 2.

Observed mean change from baseline to Week 160 in total and subscale HRQoL scores by treatment arm for IWQOL‐Lite and SF‐36

Summary/subscale score	Liraglutide 3.0 mg			Placebo
	n	Mean score at baseline	Change from baseline at Week 160	n	Mean score at baseline	Change from baseline at Week 160
IWQOL‐Lite total	1117	72.13	10.96	517	70.71	8.11
Physical function	1117	66.72	13.19	518	65.20	9.59
Self‐esteem	1119	62.18	14.78	518	59.43	11.82
Sexual life	1092	76.64	9.29	508	76.30	6.16
Public distress	1119	83.44	5.99	518	82.43	4.34
Work	1115	85.91	5.87	516	85.55	4.42
SF‐36 PCS	993	47.28	3.10	469	46.57	2.61
SF‐36 MCS	993	53.90	−0.46	469	54.00	−1.40
Physical functioning	996	47.07	3.50	470	46.42	2.48
Role physical	996	49.14	2.43	470	48.72	2.12
Bodily pain	996	50.16	0.82	470	49.51	0.51
General health	995	48.74	2.25	469	48.11	1.39
Vitality	995	52.35	1.84	470	51.80	1.07
Social functioning	995	51.55	0.25	470	51.94	−0.51
Role emotional	996	51.28	0.38	470	51.50	−0.60
Mental health	995	53.28	0.19	470	52.78	−0.81

n, number of subjects; %, percentages are based on n; missing data are imputed using last observation carried forward; scores are on a scale 0–100 whereby 0 = worst and 100 = best. HRQoL, health‐related quality of life; IWQOL‐Lite, Impact of Weight on Quality of Life‐Lite; MCS, mental component summary; PCS, physical component summary; SF‐36, Short‐Form 36 v2.